Global Breast Cancer Screening
Global Breast Cancer Screening

Breast Cancer Screening Comprehensive Study by Type (Mammography Screening, Breast Magnetic Resonance Imaging (MRI) Screening, Breast Ultrasound Screening), End User (Research Labs, Cancer Institutes, Diagnostic Centers, Others) Players and Region - Global Market Outlook to 2025

Breast Cancer Screening Market Segmented into XX Submarkets. | Forecast Years: 2020- 2025  

Nov 2020 Edition 246 Pages 222 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Industry Background:
The Brest cancer screening test is a medical screening of as asymptomatic, which is carried out to detect cancer in its early stage and ensure the medical treatment effectively. The breast cancer screening test is offered for women aged between 50-70 years as they are likely to porn to the diseases. Breast cancer has been growing significantly and is one of the most common cancers among women globally. According to WHO, Cancer is the second leading cause of death globally and responsible for an estimate of 9.6 Million death in 2018. And, Approximately 70% of death has caused by cancer which has occurred in low and middle-income countries.This growth is primarily driven by Growing Incidence of Breast Cancer and Related Disease Death, Increasing Awareness of Early Detection of Breast Cancer, Government Initiatives and National Level Program Organized and Growth in the Number of Private Diagnostic Centers.

Globally, a noticeable market trend is evident Technology Advancements in Breast Cancer Screening and Artificial Intelligence . Major Players, such as A & G Pharmacuetical Inc. (United States), Agendia BV (Netherlands), Myriad Genetics (United States), Metabolomic Technologies Inc. (Canada), Roche Holding AG (Switzerland), Biocrates Life Science AG (Austria), Hologic (United States), GE Healthcare (United States), Siemen Healthineers (Germany) and Philips Healthcare Informatics (United States) etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

Key Developments in the Market:
In November 2017, Hologic, Inc. has provided all mammography systems for the Dutch Breast Cancer Screening Program in partnership with Tromp Medical.
In November 2018, Sabre, the global leader in consumer safety and law enforcement products has raised more than USD 1.7 Million for National Breast Cancer Foundation. A mission-driven organization and partners of NBCF, SABRE empowered people to enjoy their lifestyle. The proceeds and successful implementation has recently helped launch the National Mammography Program which has provided almost 300,000 screening and diagnostic services to women in need.

Regulatory Insights:
According to WHO Breast cancer is the most frequent cancer among women, impacting 2.1 million women each year, and also causes the greatest number of cancer-related deaths among women. In 2018, it is estimated that 627,000 women died from breast cancer that is approximately 15% of all cancer deaths among women. The screening consist of testing women to identify cancers before any symptoms appear. Various methods have been evaluated as breast cancer screening tools, including mammography, clinical breast exam and breast self-exam.

Market Drivers
  • Growing Incidence of Breast Cancer and Related Disease Death
  • Increasing Awareness of Early Detection of Breast Cancer
  • Government Initiatives and National Level Program Organized
  • Growth in the Number of Private Diagnostic Centers

Market Trend
  • Technology Advancements in Breast Cancer Screening and Artificial Intelligence
  • Personalized Approach to Breast Screening

Restraints
  • Stringent Rules and Regulations For Breast Cancer Screening
  • High Cost Involved in Breast Cancer Screening Affecting Their Rate of Adoption in Emerging Market

Opportunities
Improving Healthcare Infrastructure in Emerging Market and Miniaturization and Technologies Advancements
Challenges
Hospital Budget Cuts A Key Challenge to Market Players and Lack of Skilled and Experienced Personnels

AdvanceMarketAnalytics follow a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcase the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyse the products and services offered by multiple players competing to increase their market share and presence.

Customization of the Report:
AMA Research & Media features not only specific market forecasts, but also include significant value-added commentary on:
Market Trends
Technological Trends and Innovations
Regulatory Trends & Policies
Market Maturity Indicators
Market Share Movements
Growth Drivers and Constraints
New Entrants into the Market & Entry/Exit Barriers
Consumer Demographics
Supporting Company Financial and Cash Flow Planning
Open Up New Markets
To Seize Powerful Market Opportunities
Key Decision in Planning and to Further Expand Market Share
Identify Key Business Segments, Market Proposition & Gap Analysis
Report Objectives / Segmentation Covered
By Type
  • Mammography Screening
  • Breast Magnetic Resonance Imaging (MRI) Screening
  • Breast Ultrasound Screening
By End User
  • Research Labs
  • Cancer Institutes
  • Diagnostic Centers
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Incidence of Breast Cancer and Related Disease Death
      • 3.2.2. Increasing Awareness of Early Detection of Breast Cancer
      • 3.2.3. Government Initiatives and National Level Program Organized
      • 3.2.4. Growth in the Number of Private Diagnostic Centers
    • 3.3. Market Challenges
      • 3.3.1. Hospital Budget Cuts A Key Challenge to Market Players
      • 3.3.2. Lack of Skilled and Experienced Personnels
    • 3.4. Market Trends
      • 3.4.1. Technology Advancements in Breast Cancer Screening and Artificial Intelligence
      • 3.4.2. Personalized Approach to Breast Screening
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Breast Cancer Screening, by Type, End User and Region (value) (2014-2019)
    • 5.1. Introduction
    • 5.2. Global Breast Cancer Screening (Value)
      • 5.2.1. Global Breast Cancer Screening by: Type (Value)
        • 5.2.1.1. Mammography Screening
        • 5.2.1.2. Breast Magnetic Resonance Imaging (MRI) Screening
        • 5.2.1.3. Breast Ultrasound Screening
      • 5.2.2. Global Breast Cancer Screening by: End User (Value)
        • 5.2.2.1. Research Labs
        • 5.2.2.2. Cancer Institutes
        • 5.2.2.3. Diagnostic Centers
        • 5.2.2.4. Others
      • 5.2.3. Global Breast Cancer Screening Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
  • 6. Breast Cancer Screening: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2019)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. A & G Pharmacuetical Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Agendia BV (Netherlands)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Myriad Genetics (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Metabolomic Technologies Inc. (Canada)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Roche Holding AG (Switzerland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Biocrates Life Science AG (Austria)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Hologic (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. GE Healthcare (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Siemen Healthineers (Germany)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Philips Healthcare Informatics (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Breast Cancer Screening Sale, by Type, End User and Region (value) (2020-2025)
    • 7.1. Introduction
    • 7.2. Global Breast Cancer Screening (Value)
      • 7.2.1. Global Breast Cancer Screening by: Type (Value)
        • 7.2.1.1. Mammography Screening
        • 7.2.1.2. Breast Magnetic Resonance Imaging (MRI) Screening
        • 7.2.1.3. Breast Ultrasound Screening
      • 7.2.2. Global Breast Cancer Screening by: End User (Value)
        • 7.2.2.1. Research Labs
        • 7.2.2.2. Cancer Institutes
        • 7.2.2.3. Diagnostic Centers
        • 7.2.2.4. Others
      • 7.2.3. Global Breast Cancer Screening Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Breast Cancer Screening: by Type(USD Million)
  • Table 2. Breast Cancer Screening Mammography Screening , by Region USD Million (2014-2019)
  • Table 3. Breast Cancer Screening Breast Magnetic Resonance Imaging (MRI) Screening , by Region USD Million (2014-2019)
  • Table 4. Breast Cancer Screening Breast Ultrasound Screening , by Region USD Million (2014-2019)
  • Table 5. Breast Cancer Screening: by End User(USD Million)
  • Table 6. Breast Cancer Screening Research Labs , by Region USD Million (2014-2019)
  • Table 7. Breast Cancer Screening Cancer Institutes , by Region USD Million (2014-2019)
  • Table 8. Breast Cancer Screening Diagnostic Centers , by Region USD Million (2014-2019)
  • Table 9. Breast Cancer Screening Others , by Region USD Million (2014-2019)
  • Table 10. South America Breast Cancer Screening, by Country USD Million (2014-2019)
  • Table 11. South America Breast Cancer Screening, by Type USD Million (2014-2019)
  • Table 12. South America Breast Cancer Screening, by End User USD Million (2014-2019)
  • Table 13. Brazil Breast Cancer Screening, by Type USD Million (2014-2019)
  • Table 14. Brazil Breast Cancer Screening, by End User USD Million (2014-2019)
  • Table 15. Argentina Breast Cancer Screening, by Type USD Million (2014-2019)
  • Table 16. Argentina Breast Cancer Screening, by End User USD Million (2014-2019)
  • Table 17. Rest of South America Breast Cancer Screening, by Type USD Million (2014-2019)
  • Table 18. Rest of South America Breast Cancer Screening, by End User USD Million (2014-2019)
  • Table 19. Asia Pacific Breast Cancer Screening, by Country USD Million (2014-2019)
  • Table 20. Asia Pacific Breast Cancer Screening, by Type USD Million (2014-2019)
  • Table 21. Asia Pacific Breast Cancer Screening, by End User USD Million (2014-2019)
  • Table 22. China Breast Cancer Screening, by Type USD Million (2014-2019)
  • Table 23. China Breast Cancer Screening, by End User USD Million (2014-2019)
  • Table 24. Japan Breast Cancer Screening, by Type USD Million (2014-2019)
  • Table 25. Japan Breast Cancer Screening, by End User USD Million (2014-2019)
  • Table 26. India Breast Cancer Screening, by Type USD Million (2014-2019)
  • Table 27. India Breast Cancer Screening, by End User USD Million (2014-2019)
  • Table 28. South Korea Breast Cancer Screening, by Type USD Million (2014-2019)
  • Table 29. South Korea Breast Cancer Screening, by End User USD Million (2014-2019)
  • Table 30. Taiwan Breast Cancer Screening, by Type USD Million (2014-2019)
  • Table 31. Taiwan Breast Cancer Screening, by End User USD Million (2014-2019)
  • Table 32. Australia Breast Cancer Screening, by Type USD Million (2014-2019)
  • Table 33. Australia Breast Cancer Screening, by End User USD Million (2014-2019)
  • Table 34. Rest of Asia-Pacific Breast Cancer Screening, by Type USD Million (2014-2019)
  • Table 35. Rest of Asia-Pacific Breast Cancer Screening, by End User USD Million (2014-2019)
  • Table 36. Europe Breast Cancer Screening, by Country USD Million (2014-2019)
  • Table 37. Europe Breast Cancer Screening, by Type USD Million (2014-2019)
  • Table 38. Europe Breast Cancer Screening, by End User USD Million (2014-2019)
  • Table 39. Germany Breast Cancer Screening, by Type USD Million (2014-2019)
  • Table 40. Germany Breast Cancer Screening, by End User USD Million (2014-2019)
  • Table 41. France Breast Cancer Screening, by Type USD Million (2014-2019)
  • Table 42. France Breast Cancer Screening, by End User USD Million (2014-2019)
  • Table 43. Italy Breast Cancer Screening, by Type USD Million (2014-2019)
  • Table 44. Italy Breast Cancer Screening, by End User USD Million (2014-2019)
  • Table 45. United Kingdom Breast Cancer Screening, by Type USD Million (2014-2019)
  • Table 46. United Kingdom Breast Cancer Screening, by End User USD Million (2014-2019)
  • Table 47. Netherlands Breast Cancer Screening, by Type USD Million (2014-2019)
  • Table 48. Netherlands Breast Cancer Screening, by End User USD Million (2014-2019)
  • Table 49. Rest of Europe Breast Cancer Screening, by Type USD Million (2014-2019)
  • Table 50. Rest of Europe Breast Cancer Screening, by End User USD Million (2014-2019)
  • Table 51. MEA Breast Cancer Screening, by Country USD Million (2014-2019)
  • Table 52. MEA Breast Cancer Screening, by Type USD Million (2014-2019)
  • Table 53. MEA Breast Cancer Screening, by End User USD Million (2014-2019)
  • Table 54. Middle East Breast Cancer Screening, by Type USD Million (2014-2019)
  • Table 55. Middle East Breast Cancer Screening, by End User USD Million (2014-2019)
  • Table 56. Africa Breast Cancer Screening, by Type USD Million (2014-2019)
  • Table 57. Africa Breast Cancer Screening, by End User USD Million (2014-2019)
  • Table 58. North America Breast Cancer Screening, by Country USD Million (2014-2019)
  • Table 59. North America Breast Cancer Screening, by Type USD Million (2014-2019)
  • Table 60. North America Breast Cancer Screening, by End User USD Million (2014-2019)
  • Table 61. United States Breast Cancer Screening, by Type USD Million (2014-2019)
  • Table 62. United States Breast Cancer Screening, by End User USD Million (2014-2019)
  • Table 63. Canada Breast Cancer Screening, by Type USD Million (2014-2019)
  • Table 64. Canada Breast Cancer Screening, by End User USD Million (2014-2019)
  • Table 65. Mexico Breast Cancer Screening, by Type USD Million (2014-2019)
  • Table 66. Mexico Breast Cancer Screening, by End User USD Million (2014-2019)
  • Table 67. Company Basic Information, Sales Area and Its Competitors
  • Table 68. Company Basic Information, Sales Area and Its Competitors
  • Table 69. Company Basic Information, Sales Area and Its Competitors
  • Table 70. Company Basic Information, Sales Area and Its Competitors
  • Table 71. Company Basic Information, Sales Area and Its Competitors
  • Table 72. Company Basic Information, Sales Area and Its Competitors
  • Table 73. Company Basic Information, Sales Area and Its Competitors
  • Table 74. Company Basic Information, Sales Area and Its Competitors
  • Table 75. Company Basic Information, Sales Area and Its Competitors
  • Table 76. Company Basic Information, Sales Area and Its Competitors
  • Table 77. Breast Cancer Screening: by Type(USD Million)
  • Table 78. Breast Cancer Screening Mammography Screening , by Region USD Million (2020-2025)
  • Table 79. Breast Cancer Screening Breast Magnetic Resonance Imaging (MRI) Screening , by Region USD Million (2020-2025)
  • Table 80. Breast Cancer Screening Breast Ultrasound Screening , by Region USD Million (2020-2025)
  • Table 81. Breast Cancer Screening: by End User(USD Million)
  • Table 82. Breast Cancer Screening Research Labs , by Region USD Million (2020-2025)
  • Table 83. Breast Cancer Screening Cancer Institutes , by Region USD Million (2020-2025)
  • Table 84. Breast Cancer Screening Diagnostic Centers , by Region USD Million (2020-2025)
  • Table 85. Breast Cancer Screening Others , by Region USD Million (2020-2025)
  • Table 86. South America Breast Cancer Screening, by Country USD Million (2020-2025)
  • Table 87. South America Breast Cancer Screening, by Type USD Million (2020-2025)
  • Table 88. South America Breast Cancer Screening, by End User USD Million (2020-2025)
  • Table 89. Brazil Breast Cancer Screening, by Type USD Million (2020-2025)
  • Table 90. Brazil Breast Cancer Screening, by End User USD Million (2020-2025)
  • Table 91. Argentina Breast Cancer Screening, by Type USD Million (2020-2025)
  • Table 92. Argentina Breast Cancer Screening, by End User USD Million (2020-2025)
  • Table 93. Rest of South America Breast Cancer Screening, by Type USD Million (2020-2025)
  • Table 94. Rest of South America Breast Cancer Screening, by End User USD Million (2020-2025)
  • Table 95. Asia Pacific Breast Cancer Screening, by Country USD Million (2020-2025)
  • Table 96. Asia Pacific Breast Cancer Screening, by Type USD Million (2020-2025)
  • Table 97. Asia Pacific Breast Cancer Screening, by End User USD Million (2020-2025)
  • Table 98. China Breast Cancer Screening, by Type USD Million (2020-2025)
  • Table 99. China Breast Cancer Screening, by End User USD Million (2020-2025)
  • Table 100. Japan Breast Cancer Screening, by Type USD Million (2020-2025)
  • Table 101. Japan Breast Cancer Screening, by End User USD Million (2020-2025)
  • Table 102. India Breast Cancer Screening, by Type USD Million (2020-2025)
  • Table 103. India Breast Cancer Screening, by End User USD Million (2020-2025)
  • Table 104. South Korea Breast Cancer Screening, by Type USD Million (2020-2025)
  • Table 105. South Korea Breast Cancer Screening, by End User USD Million (2020-2025)
  • Table 106. Taiwan Breast Cancer Screening, by Type USD Million (2020-2025)
  • Table 107. Taiwan Breast Cancer Screening, by End User USD Million (2020-2025)
  • Table 108. Australia Breast Cancer Screening, by Type USD Million (2020-2025)
  • Table 109. Australia Breast Cancer Screening, by End User USD Million (2020-2025)
  • Table 110. Rest of Asia-Pacific Breast Cancer Screening, by Type USD Million (2020-2025)
  • Table 111. Rest of Asia-Pacific Breast Cancer Screening, by End User USD Million (2020-2025)
  • Table 112. Europe Breast Cancer Screening, by Country USD Million (2020-2025)
  • Table 113. Europe Breast Cancer Screening, by Type USD Million (2020-2025)
  • Table 114. Europe Breast Cancer Screening, by End User USD Million (2020-2025)
  • Table 115. Germany Breast Cancer Screening, by Type USD Million (2020-2025)
  • Table 116. Germany Breast Cancer Screening, by End User USD Million (2020-2025)
  • Table 117. France Breast Cancer Screening, by Type USD Million (2020-2025)
  • Table 118. France Breast Cancer Screening, by End User USD Million (2020-2025)
  • Table 119. Italy Breast Cancer Screening, by Type USD Million (2020-2025)
  • Table 120. Italy Breast Cancer Screening, by End User USD Million (2020-2025)
  • Table 121. United Kingdom Breast Cancer Screening, by Type USD Million (2020-2025)
  • Table 122. United Kingdom Breast Cancer Screening, by End User USD Million (2020-2025)
  • Table 123. Netherlands Breast Cancer Screening, by Type USD Million (2020-2025)
  • Table 124. Netherlands Breast Cancer Screening, by End User USD Million (2020-2025)
  • Table 125. Rest of Europe Breast Cancer Screening, by Type USD Million (2020-2025)
  • Table 126. Rest of Europe Breast Cancer Screening, by End User USD Million (2020-2025)
  • Table 127. MEA Breast Cancer Screening, by Country USD Million (2020-2025)
  • Table 128. MEA Breast Cancer Screening, by Type USD Million (2020-2025)
  • Table 129. MEA Breast Cancer Screening, by End User USD Million (2020-2025)
  • Table 130. Middle East Breast Cancer Screening, by Type USD Million (2020-2025)
  • Table 131. Middle East Breast Cancer Screening, by End User USD Million (2020-2025)
  • Table 132. Africa Breast Cancer Screening, by Type USD Million (2020-2025)
  • Table 133. Africa Breast Cancer Screening, by End User USD Million (2020-2025)
  • Table 134. North America Breast Cancer Screening, by Country USD Million (2020-2025)
  • Table 135. North America Breast Cancer Screening, by Type USD Million (2020-2025)
  • Table 136. North America Breast Cancer Screening, by End User USD Million (2020-2025)
  • Table 137. United States Breast Cancer Screening, by Type USD Million (2020-2025)
  • Table 138. United States Breast Cancer Screening, by End User USD Million (2020-2025)
  • Table 139. Canada Breast Cancer Screening, by Type USD Million (2020-2025)
  • Table 140. Canada Breast Cancer Screening, by End User USD Million (2020-2025)
  • Table 141. Mexico Breast Cancer Screening, by Type USD Million (2020-2025)
  • Table 142. Mexico Breast Cancer Screening, by End User USD Million (2020-2025)
  • Table 143. Research Programs/Design for This Report
  • Table 144. Key Data Information from Secondary Sources
  • Table 145. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Breast Cancer Screening: by Type USD Million (2014-2019)
  • Figure 5. Global Breast Cancer Screening: by End User USD Million (2014-2019)
  • Figure 6. South America Breast Cancer Screening Share (%), by Country
  • Figure 7. Asia Pacific Breast Cancer Screening Share (%), by Country
  • Figure 8. Europe Breast Cancer Screening Share (%), by Country
  • Figure 9. MEA Breast Cancer Screening Share (%), by Country
  • Figure 10. North America Breast Cancer Screening Share (%), by Country
  • Figure 11. Global Breast Cancer Screening share by Players 2019 (%)
  • Figure 12. Global Breast Cancer Screening share by Players (Top 3) 2019(%)
  • Figure 13. Global Breast Cancer Screening share by Players (Top 5) 2019(%)
  • Figure 14. BCG Matrix for key Companies
  • Figure 15. A & G Pharmacuetical Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 16. A & G Pharmacuetical Inc. (United States) Revenue: by Geography 2019
  • Figure 17. Agendia BV (Netherlands) Revenue, Net Income and Gross profit
  • Figure 18. Agendia BV (Netherlands) Revenue: by Geography 2019
  • Figure 19. Myriad Genetics (United States) Revenue, Net Income and Gross profit
  • Figure 20. Myriad Genetics (United States) Revenue: by Geography 2019
  • Figure 21. Metabolomic Technologies Inc. (Canada) Revenue, Net Income and Gross profit
  • Figure 22. Metabolomic Technologies Inc. (Canada) Revenue: by Geography 2019
  • Figure 23. Roche Holding AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 24. Roche Holding AG (Switzerland) Revenue: by Geography 2019
  • Figure 25. Biocrates Life Science AG (Austria) Revenue, Net Income and Gross profit
  • Figure 26. Biocrates Life Science AG (Austria) Revenue: by Geography 2019
  • Figure 27. Hologic (United States) Revenue, Net Income and Gross profit
  • Figure 28. Hologic (United States) Revenue: by Geography 2019
  • Figure 29. GE Healthcare (United States) Revenue, Net Income and Gross profit
  • Figure 30. GE Healthcare (United States) Revenue: by Geography 2019
  • Figure 31. Siemen Healthineers (Germany) Revenue, Net Income and Gross profit
  • Figure 32. Siemen Healthineers (Germany) Revenue: by Geography 2019
  • Figure 33. Philips Healthcare Informatics (United States) Revenue, Net Income and Gross profit
  • Figure 34. Philips Healthcare Informatics (United States) Revenue: by Geography 2019
  • Figure 35. Global Breast Cancer Screening: by Type USD Million (2020-2025)
  • Figure 36. Global Breast Cancer Screening: by End User USD Million (2020-2025)
  • Figure 37. South America Breast Cancer Screening Share (%), by Country
  • Figure 38. Asia Pacific Breast Cancer Screening Share (%), by Country
  • Figure 39. Europe Breast Cancer Screening Share (%), by Country
  • Figure 40. MEA Breast Cancer Screening Share (%), by Country
  • Figure 41. North America Breast Cancer Screening Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • A & G Pharmacuetical Inc. (United States)
  • Agendia BV (Netherlands)
  • Myriad Genetics (United States)
  • Metabolomic Technologies Inc. (Canada)
  • Roche Holding AG (Switzerland)
  • Biocrates Life Science AG (Austria)
  • Hologic (United States)
  • GE Healthcare (United States)
  • Siemen Healthineers (Germany)
  • Philips Healthcare Informatics (United States)
Additional players considered in the study are as follows:
Canon Medical System Corporation (Japan) , Fujifilm (Japan) , Metaltronica (Italy) , Sino Medical-Device (China) , IMS Srl (Italy)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation